



**Editor-in-Chief**  
Pedro T Ramirez (USA)

**Associate Editors**  
Antonio Gonzalez (Spain)  
Anna Fagotti (Italy)  
Michael Frumovitz (USA)  
Rene Pareja (Colombia)  
Anuja Jhingran (USA)

**Video Editor**  
Luis Chiva (Spain)

**Social Media Editor**  
Ane Gerda Zahl Eriksson (Norway)

**Managing Editor**  
Lindsey Struckmeyer (USA)

**Editorial Office**  
*International Journal of Gynecological Cancer*, BMJ Journals  
Two Hudson Square, 3rd Floor,  
Hoboken, NJ 07030 USA  
E: [ijgc@jgeditorial.com](mailto:ijgc@jgeditorial.com)

**Production Editor**  
Hannah Martin  
E: [production.ijgc@bmj.com](mailto:production.ijgc@bmj.com)

**Customer support**  
For general queries and support with  
existing and new subscriptions:  
W: [support.bmj.com](http://support.bmj.com)  
T: +44 (0)20 7111 1105  
E: [support@bmj.com](mailto:support@bmj.com)

Self-archiving and permissions  
W: [bmj.com/company/products/services/rights-and-licensing/](http://bmj.com/company/products/services/rights-and-licensing/)  
E: [bmj.permissions@bmj.com](mailto:bmj.permissions@bmj.com)

**Disclaimer:** The Editor of *International Journal of Gynecological Cancer* has been granted editorial freedom and *International Journal of Gynecological Cancer* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *International Journal of Gynecological Cancer* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *International Journal of Gynecological Cancer* does not imply endorsement. Neither *International Gynecologic Cancer Society* and *European Society of Gynaecological Oncology* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *International Journal of Gynecological Cancer* (except for liability which cannot be legally excluded).

**Copyright:** © 2020 IGCS and ESGO. All rights reserved; no part of this publication may be reproduced in any form without permission.

*The International Journal of Gynecological Cancer (IJGC)* is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

## Lead article

- 1855** Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB–IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study  
*S Marnitz, A T Tsunoda, P Martus, M Vieira, R J Affonso Junior, J Nunes, V Budach, H Hertel, A Mustea, J Sehoul, J-P Scharf, U Ulrich, A Ebert, I Pivovonski, C Kohler*

## Editorial

- 1862** Surgical staging, the meaning of life, and other existential ponderings  
*M Frumovitz*

## Cervical Cancer

- 1864** Survival after minimally invasive surgery in early cervical cancer: is the intra-uterine manipulator to blame?  
*A Nica, S R Kim, L T Gien, A Covens, M Q Bernardini, G Bouchard-Fortier, R Kupets, T May, D Vicus, S Laframboise, L Hogen, M C Cusimano, S E Ferguson*
- 1871** Standard ultrastaging compared to one-step nucleic acid amplification (OSNA) for the detection of sentinel lymph node metastases in early stage cervical cancer  
*A Santoro, G Angelico, F Inzani, D Arciuolo, S Spadola, M Valente, N D'Alessandris, A Piermattei, V Fiorentino, F Cianfrini, N Bizzarri, L Pedone Anchora, A Fagotti, G Scambia, G F Zannoni*
- 1878** Efficacy and toxicity of postoperative external beam radiotherapy or chemoradiation for early-stage cervical cancer  
*M J E van den Akker, N Horeweg, J J Beltman, C L Creutzberg, R A Nout*
- 1887** Health-related quality of life among cervical cancer patients in India  
*G Jyani, A S Chauhan, B Rai, S Ghoshal, R Srinivasan, S Prinja*

## Uterine Cancer

- 1893** Race-driven survival differential in women diagnosed with endometrial cancers in the USA  
*Z D Horne, S R Teterichko, S M Glaser, R E Wegner, S Hasan, S M Crafton, E M Miller, T C Krivak, A Viswanathan, A B Olawaiye, P Sukumvanich, S Berwal*
- 1902** Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer  
*Y He, Y Wang, R Zhou, J Wang*
- 1908** Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes  
*A Smart, D Buscariollo, G Alban, I Buzurovic, T Cheng, J Pretz, B Krechmer, M King, L Lee*

## Ovarian Cancer

- 1915** Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study  
*Y L Liu, Q C Zhou, A Iasonos, D S Chi, O Zivanovic, Y Sonoda, G Gardner, V Broach, R O'Ceirbhail, J A Konner, R Grisham, C A Aghajanian, N R Abu-Rustum, W Tew, K Long Roche*
- 1922** Relationship status and other demographic influences on survival in patients with ovarian cancer  
*A B Gardner, B E Sanders, A K Mann, C-I Liao, R N Eskander, D S Kapp, J K Chan*
- 1928** Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer  
*S N Koole, L Bruijs, C Fabris, K Sikorska, M Engbersen, J H Schagen van Leeuwen, H W R Schreuder, R H Hermans, J van der Velden, H J G Arts, M van Ham, P Van Dam, P Vuylsteke, M Lahaye, G Sonke, W van Driel*

- 1935** Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer  
*S-E Yao, L Tripcony, K Sanday, J Robertson, L Perrin, N Chetty, R Land, A Garrett, A Obermair, M Nascimento, A Tang, N Jagasia, P Singh, J Nicklin*
- 1943** Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer  
*S I Kim, E J Lee, M Lee, H Chung, J-W Kim, N H Park, Y-S Song, H S Kim*
- 1951** Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers  
*S R Kim, A Tone, R Kim, M Cesari, B Clarke, L Eiriksson, T Hart, M Aronson, S Holter, A Lytwyn, M Maganti, L Oldfield, S Gallinger, M Q Bernardini, A M Oza, B Djordjevic, J Lerner-Ellis, E Van de Laar, D Vicus, T J Pugh, A Pollett, S E Ferguson*
- 1959** Are trainees working in obstetrics and gynecology confident and competent in the care of frail gynecological oncology patients?  
*G L Owens, V Sivalingam, M Abdelrahman, J P Beirne, D Blake, A Collins, R Davies, J Dilley, M Farquharson, D Frimpong, N Gomes, S Hawco, N Ilenkovan, E Jones, S E F Jones, T Khan, E Leung, M Otify, L Parnell, M P Rimmer, N Ryan, P Sanderson, L Stocker, M Wilkinson, S Wong, R Bharathan, Y-L L Wan, The Audit and Research in Gynaecological Oncology (ARGO) Collaborative*

## Surgery

- 1966** EVAN-G score in patients undergoing minimally invasive gynecology oncologic surgery in an Enhanced Recovery After Surgery (ERAS) program  
*D Ferraioli, C Pouliquen, C Jauffret, A Charavil, G Blache, M Faucher, G Houvenaeghel, H El Hajj, E Lambaudie*
- 1975** Role of predictive markers for severe postoperative complications in gynecological cancer surgery: a prospective study (RISC-Gyn Trial)  
*M G Inci, R Richter, H Woopen, J Rasch, K Heise, L Anders, K Mueller, S Nasser, T Siepmann, J Sehouli*

## Reviews

- 1983** Psychosexual morbidity in women with ovarian cancer  
*C A Logue, J Pugh, G Jayson*
- 1990** Transgender patients: considerations for routine gynecologic care and cancer screening  
*T Labanca, I Mañero, M Pannunzio*

## Clinical trials

- 1997** Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)  
*P Harter, P Pautier, E Van Nieuwenhuysen, A Reuss, A Redondo, K Lindemann, C Kurzeder, E Petru, F Heitz, J Sehouli, N Degregorio, P Wimberger, A Burges, N Cron, J Ledermann, D Lorusso, X Paoletti, F Marme*
- 2002** PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer  
*A S V M van den Heerik, N Horeweg, R A Nout, L C H W Lutgens, E M van der Steen-Banasik, G H Westerveld, H A van den Berg, A Slot, F L A Koppe, S Kommoss, J W M Mens, M E Nowee, S Bijmolt, D Cibula, T C Stam, I M Jurgenliemk-Schulz, A Snyers, M Hamann, A G Zwaneburg, V L M A Coen, K Vandecasteele, C Gillham, C Chargari, K W Verhoeven-Adema, H Putter, W B van den Hout, B G Wortman, H W Nijman, T Bosse, C L Creutzberg*

## Case study

- 2008** Uterine rupture: an unusual presentation of a uterine perivascular epithelioid cell tumor (PEComa)  
*J M V Nguyen, H Ghandehari, C Parra-Herran, D Vicus*

## Corners of the world

- 2012** Patient engagement in research on rare gynecological tumors  
*J Roze, J Groeneweg, G Monroe, I Fransen, M Gultekin, R Zweemer, R H M Verheijen*

---

**Video articles**

- 2015** Vaginal reconstruction after pelvic exenteration with a vertical deep inferior epigastric perforator flap in 10 steps

*M A Angeles, C Martínez-Gómez, A Martínez, T Meresse, D Gangloff, G Ferron*

- 2017** Challenges of laparoscopic lymphadenectomy for cervical cancer in pregnant women: techniques and tips

*Y Nagase, E Kobayashi, T Takiuchi, M Kodama, S Nakagawa, M Endo, T Kimura*

---

**Letters**

- 2019** The right question in the right database: epidural analgesia for gynecological oncologic surgery

*C F Weiniger, M Cooter, A S Habib*

- 2020** Rebuttal for: Postoperative complications of epidural analgesia at hysterectomy for gynecologic malignancies: an analysis of the National Surgical Quality Improvement Program

*P K Kooner, L Bollag, W Van Cleve*

- 2021** Reply to “Rebuttal for: Postoperative complications of epidural analgesia at hysterectomy for gynecologic malignancies: an analysis of the National Surgical Quality Improvement Program”

*S A Ackroyd, E Hernandez, K Houck*

---

**Miscellaneous**

- 2022** Correction: *Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia*

- 2023** Correction: *Prognostic factors in patients with vulvar cancer: the VULCAN study*